临床肝胆病杂志2013，Vol.29Issue(7)：496-498,3.DOI:10.3969/j.issn.1001-5256.2013.07.005
自身免疫性胰腺炎的治疗进展
Advances in treatment of autoimmune pancreatitis
摘要
Abstract
Autoimmune pancreatitis (AIP) is a type of chronic pancreatitis characterized by an autoimmune inflammatory process.Treatment protocols for AIP are still evolving.According to the articles about AIP treatment in recent years,the indications for steroid therapy include specific clinical manifestations (jaundice,abdominal pain,etc.),markedly abnormal imaging findings,and extrapancreatic organ involvement.The initial dose of steroid (prednisone) is usually 0.6 mg · kg-1 · d-1 or 30-40 mg/d ; after 3 weeks to 1 month of treatment with the initial dose,the dose is decreased by 5-10 mg every 1-2 weeks until it drops to 2.5-5 mg/d; this dose is maintained for 6 months to 3 years.No consensus has been reached on the adverse effect of steroid on diabetes mellitus complicating AIP.Immunosuppressive agents should be used for the patients with disease relapses or with important extrapancreatic organs involved.Rituximab might become one of the therapies for refractory AIP.Although some patients achieved remission after surgical treatment,surgery is still not recommended as a routine treatment protocol due to the complications after surgery.关键词
胰腺炎,慢性/自身免疫疾病/糖皮质激素类/免疫抑制剂Key words
pancreatitis, chronic / autoimmune diseases/ glucocorticoids / immunosuppressive agents分类
医药卫生引用本文复制引用
李骥,钱家鸣..自身免疫性胰腺炎的治疗进展[J].临床肝胆病杂志,2013,29(7):496-498,3.
